The KRAS inhibitor, AMG-5101 (brand name Lumakras, generic name sotorasib) recently obtained FDA approval for the treatment non-small cell lung cancer patients who have the KRAS G12C mutation. This evidence concerns the gene KRAS and non-small cell lung carcinoma.